Company Description
ImmunoPrecise Antibodies Ltd., a biotechnology company, leverages multi-omics modeling and artificial intelligence through a series proprietary and patented technologies.
The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies.
It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.
The company also offers syngeneic cell line for immunization and screening; peptide production for subsequent antibody discovery campaign; B cell select platform, which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection.
In addition, it provides phage display, a custom immune library; CAR development, an adaptable antibody, which allows the inclusion of functional data early in the screening funnel; antibody sequencing; and assay development.
Further, it offers a profiling toolset for antibody lead candidates; and in vitro analytical tools for the study of quality attributes.
Additionally, it provides LucinaTech, an antibody humanization to identify framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; antibody chimerization for cloning and production of antibody domain; Eurofins preclinical services; hybrid service model designed to reduce time and risk with custom applications; breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts; and protein manufacturing services.
The company is headquartered in Victoria, Canada.
| Country | Canada |
| Founded | 1983 |
| IPO Date | Jan 3, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 101 |
| CEO | Jennifer Bath |
Contact Details
Address: 3204–4464 Markham Street Victoria, BC V8Z 7X8 Canada | |
| Phone | 250 483 0308 |
| Website | ipatherapeutics.com |
Stock Details
| Ticker Symbol | IPA |
| Exchange | NASDAQ |
| Fiscal Year | May - April |
| Reporting Currency | CAD |
| CIK Code | 0001715925 |
| CUSIP Number | 45257F200 |
| ISIN Number | CA45257F2008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jennifer Lynne Bath Ph.D. | Chief Executive Officer, President and Non-Independent Director |
| Dr. Ilse Roodink | Chief Scientific Officer and Interim General Manager of IPA Europe, Oss |
| Kari Graber | Vice President of Commercial Services |
| Dr. Roland Romijn | Head of General Operations of the Utrecht site of IPA (Europe) |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 4, 2024 | 6-K | Report of foreign issuer |
| Oct 28, 2024 | 6-K | Report of foreign issuer |
| Oct 24, 2024 | 6-K | Report of foreign issuer |
| Oct 21, 2024 | 6-K | Report of foreign issuer |
| Oct 11, 2024 | 6-K | Report of foreign issuer |
| Oct 10, 2024 | 6-K | Report of foreign issuer |
| Oct 2, 2024 | 6-K | Report of foreign issuer |
| Sep 26, 2024 | 6-K | Report of foreign issuer |
| Sep 23, 2024 | 6-K | Report of foreign issuer |
| Sep 18, 2024 | 6-K | Report of foreign issuer |